CCR 20th anniversary commentary: Preclinical study of proteasome inhibitor bortezomib in head and neck cancer

Clin Cancer Res. 2015 Mar 1;21(5):942-3. doi: 10.1158/1078-0432.CCR-14-2550.

Abstract

In a study published in the May 1, 2001, issue of Clinical Cancer Research, Sunwoo and colleagues provided evidence for proteasome inhibition of NF-κB and tumorigenesis, supporting early-phase clinical trials in solid malignancies of the upper aerodigestive tract. Subsequent clinical studies uncovered a dichotomy of responses in patients with hematopoietic and solid malignancies, and the mechanisms of resistance.

Publication types

  • Comment

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Boronic Acids / pharmacology*
  • Humans
  • Multienzyme Complexes / antagonists & inhibitors*
  • NF-kappa B / antagonists & inhibitors*
  • Pyrazines / pharmacology*

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Multienzyme Complexes
  • NF-kappa B
  • Pyrazines